3.1. Participants
Subjects were recruited from a military medical center in Tehran. Enlistment and treatment was conducted at the clinical/research center offices of the AUMS.
Potential study subjects were distinguished through the Institutional Survey Board (ISB) and approved study materials were screened taking into account inclusion and exclusion criteria. In the event that all criteria were met, they booked for consent, and started treatment.
Inclusion criteria for study qualification included chronic low back pain (≥ 3 months term), no emanating pain underneath the knee, ≥ 75% back or buttock pain rather than lower extremity pain, and ready to finish and endure treatment for the study time frame.
Exclusion criteria included earlier history of spinal fusion or failed spinal surgery syndrome, laminectomy, laminotomy or discectomy within 12 months of enlistment, and indicative or interventional infusions or any low back surgeries not said above, including radiofrequency neuroablation inside six months of enlistment. Patients utilizing individual home based electrical stimulation gadgets were avoided. Patients with other concomitant disease (e.g. malignancy, osteoporosis, etc.), which in the assessment of the investigator would block effective patient participation, were also avoided. Patients with active psychiatric issues were also excluded (e.g. utilization of antipsychotic drugs, bipolar disorder and schizophrenia). Patients determined to have a history of significant mood disorder were avoided (e.g. use of antipsychotic medication, bipolar disorder and schizophrenia). Patients who were pregnant at the first visit became pregnant later were excluded.
Consent was acquired before start of treatment. Study subjects gave a copy of the consent record and the report was outlined in detail by a research colleague. Study subjects offered chances to make questions prior to signing the consent form and selection in the study.
3.2. Allocation Procedures
Subjects were allocated after confirming eligibility and completion of baseline data collection. Stratification was performed for opioid use (current versus past/never).
3.3. Outcome Measures
Outcome measures were taken at baseline, four, eight and 12 weeks, with the primary outcome being at four weeks. Evaluation occurred in the same manner and at the same intervals for all patients using standard strategies. Treatment failure was characterized as patients ending treatment for non-effectiveness or pursue of surgical or invasive procedures or other excluded co-interventions.
The primary outcome measure was the Oswestry disability index (ODI). The ODI is generally utilized as part of low back pain treatment trials, and gives a measure of functional change. The ODI was chosen with a subjective pain rating (
23-
25). Secondary outcome measure was the VAS pain score (0 - 10).
Data was collected at enrollment and subsequent treatments. Data after treatments termination was collected using the same tools for every participant by a blinded assessor.
3.4. Assessments
Timing of evaluations was identical for every patient. Evaluations were directed by blinded assessors. Enlistment and starting treatment occurred at the time of enlistment. All patients returned four weeks after initial treatment for evaluation of subject capacity to accurately perform the exercise, ask questions about the exercise, and to finish week four assessment. Subjective assessments were measured at baseline, and on the fourth, eighth, and twelfth week. Objective assessments were measured pre and post-treatment at baseline and post-treatment on the fourth, eighth, and twelfth week. No treatment was provided by the researchers. Patients all had the same and equivalent contact time with suppliers and assessors to minimize treatment differences. All patients were contacted on a weekly basis by a blinded assessor by phone to energize consistency and utilize day by day treatment diaries.
At every assessment, all patients received the same evaluation, including questionnaire and physical functioning assessment form. All measures evaluated utilization of computerized data collection methods at baseline and each follow-up.
3.5. Treatment Protocol
Every patient had identical quantities of visits and contact time. Every patient obtained uniform guidelines for the exercise. Patients were trained to perform the exercise every day after getting up and before sleep time, and up to two extra times during the day as required. Providers were trained in a standardized fashion to educate each participant.
There was no accepted standardized treatment found in the literature for chronic low back pain.
3.6. Compliance
Compliance was assessed by interviews and diaries. Total treatment time of 3.5 hours per week was set as the threshold for compliance. If VAS pain dropped to a daily average of less than or equal to two out of ten, patients were considered in compliance regardless of the number of treatments completed on that day. Patients were contacted once per week to promote compliance and answer questions.
3.7. Discontinuation
Subjects were encouraged to continue follow-up throughout the study. There were no penalties for early dropouts. Those who developed an adverse event were reported to the IRB.
3.8. Usual Care and Co-Interventions
Study participants were asked to avoid significant changes in medical/healthcare management of their LBP during the study period. All participants were allowed to pursue usual care with their own personal treating physician. No other treatment other than the Farshad exercise provided by the trial researchers. Usual care was limited to non-invasive therapies, including medications such as NSAIDS (prescription or over the counter) and opioids, physical therapy, manipulation, stretching and aerobic exercise. Self-applications of heat or ice were also acceptable. All usual care medications and interventions were recorded.
3.9. Interventions Not Allowed
Interventions that were not allowed included any lumbosacral invasive method, for example, discectomy, microdiscectomy, laminectomy, lumbar fusion, and disc desiccation by any chemical or thermal means. No infusions into the lumbosacral area other than localized trigger point without the utilization of glucocorticoids, and no utilization of oral or systemic glucocorticosteroids was allowed. Patients were given information about extra medicines at every assessment to determine continued eligibility.